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The Renal and Lung Living Donors Evaluation Study
assesses outcomes of live lung (lobectomy) donors.
This is a retrospective cohort study at University of
Southern California (USC) and Washington University
(WASHU) Medical Centers (1993–2006), using medical
records to assess morbidity and national databases to
ascertain postdonation survival and lung transplanta-
tion. Serious complications were defined as those that
required significant treatment, were potentially life-
threatening or led to prolonged hospitalization. The
369 live lung donors (287 USC, 82 WASHU) were
predominantly white, non-Hispanic andmale; 72% had
a biological relationship to the recipient, and 30%were
recipient parents. Serious complications occurred in
18% of donors; 2.2% underwent reoperation and 6.5%
had an early rehospitalization. The two centers had
significantly different incidences of serious complica-
tions (p< 0.001). No deaths occurred and no donors
underwent lung transplantation during 4000þ person-
years of follow-up (death: minimum 4, maximum
17 years; transplant: minimum 5, maximum 19). Live
lung donation remains a potential option for recipients
when using deceased donor lungs lacks feasibility.
However, the use of two live donors for each recipient
and the risk of morbidity associated with live lung
donation do not justify this approach when deceased
lung donors remain available. Center effects and long-
term live donor outcomes require further evaluation.
Keywords: Live donors, lung transplantation, mortali-
ty, outcomes
Abbreviations: DCC, data coordinating center; HRSA,
Health Resources and Services Administration; LAS,
lung allocation score; MMRF, Minneapolis Medical
Research Foundation; NCHS, National Center for
Health Statistics; NCI, National Cancer Institute;
NHLBI, National Heart, Lung and Blood Institute;
NIAID, National Institute of Allergy and Infectious
Diseases; NIH, National Institutes of Health; OPTN,
Organ Procurement and Transplantation Network;
RELIVE, Renal and Lung Living Donors Evaluation
Study; SRTR, Scientific Registry of Transplant Recip-
ients; SSA, Social Security Administration; SSDMF,
Social Security DeathMaster File; SSN, Social Security
Number; UNOS, United Network for Organ Sharing;
USC, University of Southern California; WASHU,
Washington University
Received 17 February 2014, revised 21 March 2014 and
accepted for publication 27 March 2014
Introduction
Inadequate donor lung allograft supply and deaths of
candidates awaiting lung transplantation led to implemen-
tation of living lobar lung donation (1) and consequent
broadening of the pool of donor organs which historically
came from deceased donors. Though the number of live
lung donations has minimally impacted the number of lung
transplants performed in the United States (2,3), live lung
donation has had a greater effect in countries like Japan that
have had low deceased donor rates (4–6). After a transient
rise in frequency in the 1990s and early 2000s, live
lung donation decreased in the United States due to
changes in the lung allocation system and effects of
medical management on transplant urgency (2). However,
live lung donation grew in frequency in some areas outside
the United States due to lack of brain death laws, continued
unavailability or acceptance of deceased donation, and
altered lung allocation policies (4–9).
Live donation confronts society with complex ethical and
medical issues regardingshort-and long-termdonor risks (10–
12). Since each live lung recipient typically has two donors,
the overall donation/transplant scenario puts three people at
risk for death and morbidity, while only one of the three (i.e.
the recipient) has a likelihood ofmedically benefiting from the
procedure. Relationships between donors, recipient and
nondonors may profoundly affect psychosocial outcomes of
all involved (13,14), and live lung donor and recipient
outcomes may further complicate matters.
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The two US centers with the greatest live lung donor
experience, University of Southern California (USC) and
Washington University (WASHU)/Barnes-Jewish Hospital,
have previously published results from short-term live
lung donor outcomes studies (15–19). Though neither
center reported any early postoperative deaths in their
donors (USC n¼253 and WASHU n¼ 62; total n¼ 315),
there was a threefold difference in morbidity incidence
between the two centers (20% at USC vs. 61% at
WASHU) (17,19).
Due to a paucity of accurate, reliable and comprehensive
outcomes data for live lung donors, potential donors do not
have robust information on which to base an informed
consent decision for undergoing donor evaluation and
surgery. In addition to limited and inconsistent data
regarding short-term donor morbidity, the long-term risk
of pulmonary dysfunction and other adverse outcomes
remains unknown. Investigators have not published results
from large-scale and long-term studies of the effects of live
lung donation on donor pulmonary function, health-related
quality of life and psychological well-being.
Limited data existed regarding comprehensive and long-
term live lung donor outcomes when the Renal and Lung
Living Donors Evaluation Study (RELIVE) began in 2006.
Between 1993 and 2006, 12 168 deceased lung donations
and 460 live lung donations occurred in the United
States (20). During that period, the USC and WASHU
transplant teams performed 369 live lung donation
operations, accounting for 80% of live lung donations in
the United States (20). This study of live lung donors
describes: (1) perioperative donor characteristics; (2) the
types and incidence of short-term complications following
live lung donation; and (3) the incidence rates of postdo-
nation mortality and the development of severe lung
disease requiring lung transplantation.
Methods
Study design/patients and setting/study eligibility criteria
Investigators conducted a retrospective cohort study of all patients from
USC (Los Angeles, CA) and WASHU (St. Louis, MO) who underwent live
lung donation (i.e. lobectomy) between January 1, 1993 and December 31,
2006. Study personnel collected donor medical record data extant through
January 31, 2007, death events that occurred through May 31, 2010, and
lung transplant events that occurred through November 30, 2011. After
review of the study protocol and approval by the RELIVE Steering
Committee and the National Institute of Allergy and Infectious Diseases,
each site and the University of Michigan data coordinating center (DCC)
obtained investigational review board (IRB) approval at their respective sites
(USC IRB approval number HS-07-00332-CR006; WASHU IRB approval
number 201101865; DCC IRB approval number CR00032674 and protocol
number HUM00004345).
Variables
Trained study personnel collected donor data for preoperative and
intraoperative characteristics, intraoperative and postoperative complica-
tions, serious and nonserious postoperative complications during the
donation hospitalization, and early rehospitalization (i.e. at the same medical
center and within 30 days after donation). The protocol defined serious
complications as those that required significant treatment (i.e. treatment
typically requiring administration in a hospital setting), were potentially life
threatening, or led to prolonged hospitalization. The protocol considered all
other complications as nonserious (i.e. not treated or easily treatable, and not
potentially life-threatening or leading to prolonged hospitalization). Two
investigators (RDY and MLB) adjudicated all complications as serious or
nonserious by consensus.
Data sources
Study personnel identified lobar donors from the medical records and
databases of the USC and WASHU programs, and they collected existing
patient data from paper and electronic medical records and databases. The
study obtained donor death and lung transplant event information from the
Social Security Death Master File and the Scientific Registry of Transplant
Recipients databases, respectively. Outcomes of donors living outside the
United States may not have been captured in the national database
searches.
Data collection methodology and quality control
Study investigators and personnel created a manual of operations, and each
site also operationalized local procedures for the study. The study used
standardized definitions for terms. DCC personnel trained the site study
coordinators. The coordinators abstracted data from paper and electronic
medical records and entered the data into an electronic database. Key
outcomes underwent central adjudication (see the Variables section). The
electronic case report form data entry system had embedded quality control
measures. The DCC addressed additional data concerns through queries to
coordinators. Chart audits confirmed source documentation and appropriate
study conduct.
Statistical analyses
Data analysis and reporting utilized descriptive statistics, chi-square
statistics to compare categorical data among groups, and two-tailed t-tests
andWilcoxon tests to compare continuous data between groups. To assess
donor selection and care learning effects at each site on complication rates,
we compared complication rates within sites based on early and late
subgroup (i.e. first 40 donors and last 40 donors at each site, and first and last
81 donors at USC); we also compared complication rates among era of
donation for the combined (USC and WASHU) cohort. We log-transformed
hospital length of stay for inferential analyses.We used logistic regression to
identify significant predictors of complications, and linear regression for
predictors of log-transformed hospital length of stay (see frequencies and
descriptive statistics in Tables S1, S2 and S3). Historical and predonation
variables tested as predictors in the models included donor age, race,
ethnicity, sex, height, weight, BMI (tested independently of height and
weight), history of alcohol/tobacco/illicit drug use, bronchodilator use,
reported lung disease (e.g. asthma), chronic pain, psychiatric conditions and
predonation pulmonary function data (i.e. percentage of predicted pre- and
postbronchodilator forced expiratory volume in one second and forced vital
capacity, total lung capacity, residual volume and diffusing capacity for
carbon monoxide). Intraoperative variables tested as predictors included
incision type, location of donated lobe, right middle sacrifice, rib removal,
stump treatment, use of a double lumen endotracheal tube, use of a
bronchoplastic procedure and medical center. We assessed model
assumptions and performed regression diagnostics. Analyses were
performed using SAS version 9.2 (SAS Institute, Cary, NC). The authors
used the Strengthening the Reporting of Observational Studies in
Epidemiology Statement (21) to guide the reporting of results. The sample
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size for this study was fixed and the study utilized data from all lung donors
during the study period at the two sites.
Reporting
We published a limited subset of data from this study in abstract form and
presented it at the 2011 American Transplant Congress (22). An older subset
of these data was reported in previous publications (17,19). However,
compared to those studies, the RELIVE study included more patients from
each center, usedmore rigorous and standardized studymethodology, had a
longer follow-up period to assess for donor death or lung transplantation, and
used national databases to assess outcomes.
Results
Donor characteristics
The study cohort consisted of 369 adult live lung donors
(287 USC, 82 WASHU) (Table 1). Donations were made to
186 recipients (145 USC, 41 WASHU). Donors were
predominantly white, non-Hispanic and male. Most had a
biological relationship to their lung transplant recipient.
About one-third of donors (n¼ 109) were parents of the
recipient. Both parents served as donors for 25 recipients
(17 at USC, 8 at WASHU). Many of the recipients were
children (age less than 18 years). USC had 48 (33%) child
recipients (age of 1 recipient was unknown) and WASHU
had 33 (80%) child recipients.
Live lung donation surgery
Based on lung size and anatomical issues, lung donation
typically consisted of removal of a single lower lobe. The
paired lung donations usually consisted of a right lower lobe
from one donor and a left lower lobe from another donor. All
but three of the recipients received lobes from two donors
to achieve a bilateral lung transplant.
Complications
One hundred fifty-six in-hospital (intraoperative or postop-
erative) serious or nonserious (e.g. nausea, pain, fever)
complications occurred in 29% (107/369) of donors.
Seventy-nine serious complications occurred in 17.6%
(65/369) of donors (Table 2 and Fig. 1); 13.8% (51/369) had
only one serious complication and 3.8% (14/369) had two
serious complications. The most common serious compli-
cation was postoperative cardiac arrhythmia that led to
treatment. Pericarditis occurred in 3.3% of donors, and this
only occurred in left side donors (p¼0.0003). Additional/
unexpected chest tube drainage was required in 3.3% of
recipients; two-thirds of these eventswere associatedwith
pneumothorax and one-third with pleural effusion and/or
bleeding. Reoperation occurred in 2.2% of donors. No
donors had tracheostomy, stroke, myocardial infarction,
sepsis or venous thromboembolism. No deaths occurred
during the donation hospitalization. The two centers had
significantly different incidences of serious complications
(p<0.001) (Fig. 1). We did not find evidence of learning
curve effects on the incidence of serious complications
either within sites or overall.
Hospital length of stay and rehospitalization
The hospital length of stay averaged 8.3 4.2 days (median
7 days; range 3–32 days) (Fig. 2). Early rehospitalizationwas
documented in 24 (6.5%) donors. However, the study
lacked complete rehospitalization reporting because some
donors did not undergo follow-up with the donor site team
after discharge from the hospital. Most documented early
Table 1: Baseline characteristics of live lung donors
Variable
USC (N¼287) WASHU (N¼82) All (N¼369)
N % N % N %
Male 186 65 46 56 232 63
Non-Hispanic 256 89 76 93 332 90
Caucasian 268 93 79 96 347 94
Relation to recipient
Biological 194 68 70 85 264 72
Parent 72 25 37 45 109 30
Sibling 52 18 9 11 61 17
Aunt/uncle 33 11 17 21 50 14
Cousin 29 10 6 7 35 9
Other 8 3 1 1 9 2
Nonbiological 86 30 12 15 98 27
Friend 59 21 5 6 64 17
Spouse 8 3 0 0 8 2
Other 19 7 7 9 26 7
Unknown 7 2 0 0 7 2
Age (range 18.2–58.5) Mean SD Mean SD Mean SD
37.1 9.8 39.5 9.8 37.6 9.8
USC, University of Southern California; WASHU, Washington University (St. Louis).
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rehospitalizations occurred in association with ongoing or
recurrent pericarditis, arrhythmia, pleural effusion or
airway/chest bleeding (Table 3).
Lung transplantation and death outcomes
No donors died or underwent lung transplantation during
follow-up that ranged from 4 to 17 years for mortality and 5
to 19 years for transplant (4267 person-years at risk for
mortality; 4820 person-years at risk for lung transplanta-
tion). Eleven donors (3.0% of 369) were not living in the
United States at the time of donation; nine (3.1% of 287)
donated at USC and two (2.4% of 82) donated at WASHU.
For four donors (1.1% of 369), all from USC (1.4%; 4/287),
we do not know whether they were living in the United
States or not.
Predictive models
A predictive logistic regressionmodel for in-hospital serious
complications identified the center as an independent
predictor (p< 0.001; Table 4). A predictive linear regression
model for log-transformed hospital length of stay (Table 5)
identified medical center (Figure 2), bronchodilator use
(ever), anterolateral incision approach and right middle lobe
sacrifice (not planned as part of the operation) as
independent predictors of longer length of stay (model
p< 0.001). Among the many assessed variables (see
Tables S1, S2 and S3), the models did not identify age,
sex or weight as significant independent predictors.
Discussion
RELIVE documented and classified morbidities associated
with live lobar lung donation in the largest cohort reported to
date that representsmost of the United States andmuch of
the international experience (5,7). No donors underwent
lung transplantation and no donor deaths occurred during
the 4000þ person-years of follow-up.
Though a minority of donors had complications, about 1 out
of 5 donors experienced a serious complication, and about 1
out of 25 experiencedmultiple serious complications. About
1 out of 50 donors required reoperation. At least 1 out of 16
donors required rehospitalizationwithin 30 days of donation.
Serious complications and hospital length of stay showed
variation between the medical centers. A preoperative
medical condition (i.e. bronchodilator use, ever) and some
operative issues (i.e. anterolateral incision approach and
right middle lobe sacrifice [not planned as part of operation])
were independent predictors of longer length of stay.
Consistent with prior reports (17,19,23), the current study
showed significant center-based differences in the
Table 2: Number of serious in-hospital complications in live lung
donors
Complication
Number of
complications
Percent of
donors with each
complication
Treated arrhythmia 13 3.5
Pericarditis1 12 3.3
Tube thoracostomy—total 12 3.3
Pneumothorax 8 2.2
Pleural effusion/bleeding 4 1.1
Reoperation 8 2.2
Pneumonia 8 2.2
Air leak 6 1.6
Intra-operative right middle
lobe sacrifice
5 1.4
Ileus 5 1.4
Blood transfusion 4 1.1
Empyema 2 0.5
Pulmonary artery thrombosis
(not pulmonary embolism)
2 0.5
Bronchial stricture 1 0.3
Cardiac arrest 1 0.3
USC, University of Southern California; WASHU, Washington
University (St. Louis).
N¼369 [287 USC, 82 WASHU].
Seventy-nine serious in-hospital complications occurred in 65 of
the 369 donors; 17.6% (65/369) had 1 serious complication;
13.8% (51/369) had only 1 serious complication and 3.8% (14/369)
had 2 serious complications.
1Pericarditis only occurred in left-sided donors (p¼0.0003).
Figure 1: Percent of donorswith in-hospital serious complica-
tions, by center.
Figure 2: Length of hospital stay (days), by center.
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occurrence of short-term postlive lung donation complica-
tions. These differences may have resulted from differ-
ences in donor selection, management and monitoring
approaches, medical record documentation and definitions
and terminology used by clinicians. Differences between
centers in the length of donation hospitalization may have
resulted from different policies or practices at each center.
The live lung donation operation differs from and is more
extensive than standard lobectomy (e.g. performed for
malignancy) because it requires removal of an adequate
cuff of bronchus, pulmonary artery and vein with the lung
lobe for successful donor lobe implantation into the
recipient. In addition, the donor’s remaining tissue must
allow for closure of these structures without compromise.
Differences in right and left side surgical approaches
appeared to affect outcomes in RELIVE. Compared to right
lower lobe donors, left lower lobe donors had a higher rate
of pericarditis that we attributed to a higher rate of
pericardial opening.
Live donor lung transplantation has rarely occurred in the
United States since implementation of the current donor
lung allocation score (LAS) system in 2005. However, even
in the LAS era, live lung donation may still have relevance
for candidates at high projected risk of waiting list mortality
and a low likelihood of obtaining deceased donor lungs (e.g.
high degree of sensitization). The recent controversial issue
of limited donor access for young pediatric lung transplant
Table 3: Discharge diagnoses for rehospitalizations within 30 days of donation
1st rehospitalization (N¼24 donors) 2nd rehospitalization (N¼3 donors)
N % N %
Primary discharge diagnosis
Pneumothorax 5 20.8 1 33.3
Pain (n¼1 atypical chest pain; n¼2 incisional) 3 12.5 0 0.0
Pneumonia 3 12.5 0 0.0
Pericarditis 2 8.3 0 0.0
Postoperative pleural effusion 2 8.3 0 0.0
Arrhythmia 1 4.2 0 0.0
Dehydration due to vomiting due to drug s/e 1 4.2 0 0.0
Empyema 1 4.2 1 33.3
Hemorrhage 1 4.2 0 0.0
Hydropneumothorax 1 4.2 0 0.0
Infection (unknown site) 1 4.2 0 0.0
Left lower lobe atelectasis 1 4.2 0 0.0
Nausea/vomiting/abdominal pain 1 4.2 0 0.0
Severe shortness of breath 1 4.2 0 0.0
Bronchopleural fistula 0 0.0 1 33.3
Secondary discharge diagnosis
Postoperative pleural effusion 2 8.3 0 0.0
Bronchopleural fistula 1 4.2 0 0.0
Elevated aPTT 1 4.2 0 0.0
Hemoptysis 1 4.2 0 0.0
Left-sided chest discomfort 1 4.2 0 0.0
Pneumonia 1 4.2 0 0.0
Pleural cavity abscess 0 0.0 1 33.3
Pneumothorax 0 0.0 1 33.3
Right pleural effusion 0 0.0 1 33.3
Unknown/missing 17 70.8 0 0.0
Tertiary discharge diagnosis
Bronchial inflammation 1 4.2 0 0.0
Pneumonia 1 4.2 0 0.0
Unknown/missing 22 91.7 3 100
USC, University of Southern California; WASHU, Washington University (St. Louis).
Total cohort N¼369 (287 USC, 82 WASHU).
Table 4: Preoperative predictors of serious in-hospital complica-
tions after live lung donation
Variable OR
Lower
95% CI
Upper
95% CI p-Value
Intercept 0.46 0.29 0.74 0.0012
Medical center 0.34 0.19 0.60 0.0002
USC, University of Southern California.
WASHU, Washington University (St. Louis).
N¼369 (287 USC, 82 WASHU); C¼0.608; model chi-square
14.43.
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candidates in the United States (24) further increases the
relevance of the option of live lung donation in certain
settings. Live lung donation may also have greater
relevance in lung transplant allocation systems that give
priority based on candidate waiting list time. In addition,
systems that have severe limitations in deceased donor
availability due to cultural (e.g. Japan) or other issues may
depend heavily on the ability to increase access to donor
lungs through live lung donation. Thus, for all donor lung
allocation systems, RELIVE has relevance and generates a
better understanding of the risks of live lung donation. Such
information will improve the informed consent process (12)
and it will hopefully improve donor selection and subse-
quently decrease donor risks.
The limitations of RELIVE include the retrospective study
design, the variability of data completeness and the
complication documentation issues outlined above. The
study protocol attempted tominimize errors in complication
ascertainment by using standardized definitions, clear data
abstraction rules and uniform study coordinator training. In
addition, the investigators reviewed and categorized all
complications through an adjudication process. The study
lacked complete follow-up after hospital discharge that
included assessment of rehospitalization and long-term
outcomes. In addition, ascertainment of mortality and lung
transplantation via the US national databases would not
capture events in donors that resided outside of the United
States. The predictive models did not undergo validation in
other patients and in other settings. The next phase of
RELIVE will utilize a cross-sectional design and incorporate
contacting the donors from this retrospective cohort study
to assess long-term donor lung function and psychosocial
outcomes and to confirm mortality and lung transplant
event rates from this study.
In conclusion, live lung donation for recipients provides an
acceptable option when use of deceased donor lungs lacks
feasibility. However, the use of two live donors for each
recipient and the risk of morbidity associated with live lung
donation do not justify this approach when deceased lung
donors are available. Center effects and long-term live
donor outcomes require further evaluation.
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